Clinical trials: Oligometastatic Prostate Cancer
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- ACCEL (NCT06229366)
- Testing
- [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
- Where
- 7 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Stereotactic Body Radiation Therapy
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor…
- Trial name
- START-MET (NCT05209243)
- Testing
- SBRT, STANDARD OF CARE
- Where
- 2 sites in Spain
- Volunteers
- 266 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer
Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high…
- Trial name
- PROST-ART (NCT06546267)
- Testing
- Image Guided Radiotherapy, Intensity Modulated Radiotherapy, Stereotactic Body Radiotherapy
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- IRCCS San Raffaele
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- PILLAR (NCT03503344)
- Testing
- Apalutamide, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- NCT03043807
- Testing
- Leuprolide Acetate, Docetaxel, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Metastatic Disease, Oligometastatic Prostate Cancer (OMPC)
HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)
The investigators propose redefining this concept by focusing on volume rather than the number of metastases. To achieve this, the investigators aim to determine the Maximum Tolerated Volume (MTV) of metastatic lesions treatable…
- Trial name
- HIMARS (NCT06978296)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
There is an increasing number of reports describing the existence of a proportion of prostate cancer patients who present with a reduced number of metastases (<5 lesions) at relapse.
- Trial name
- OLIGOPELVIS (NCT02274779)
- Testing
- ELIGARD
- Where
- 2 sites in France
- Volunteers
- 74 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical…
- Trial name
- NCT06259123
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Oligometastatic Prostate Cancer
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Currently, despite the advent of next-generation imaging has improved the detection of Oligometastatic prostate cancer (OMPC), prognostic biomarkers able to stratify patients and monitor treatment response are lacking and…
- Trial name
- PROMETEO (NCT06060652)
- Where
- 2 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Prostate Cancer, Oligometastasis
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate…
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer
- Trial name
- VA STARPORT (NCT04787744)
- Testing
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease
- Where
- 20 sites in United States
- Volunteers
- 378 people
- Sponsor
- VA Office of Research and Development
Prostatic Neoplasms
Stereotactic Radiotherapy for Oligometastatic Prostate Cancer
This is a study that assesses the safety and efficacy of using stereotactic radiotherapy in conjunction with hormone therapy for patients with metastatic prostate cancer where there are a limited number of metastatic tumours.
- Trial name
- CROP (NCT02563691)
- Testing
- stereotactic radiotherapy
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
The researchers are doing this study to find out whether giving 177Lu-PSMA-617 followed by a type of radiation therapy called SBRT (stereotactic body radiation therapy) is a safe treatment for your cancer.
- Trial name
- NCT05079698
- Testing
- 177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT)
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT06205316
- Testing
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Mayo Clinic
High Risk Prostate Cancer
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
This is a phase 2, open-label, randomized study of adjuvant treatment in subjects with high-risk prostate cancer who are candidates for RP with PLND based on M0 status at conventional imaging, but staged as oligometastatic with…
- Trial name
- STAPLE (NCT06758882)
- Testing
- Apalutamide, Androgen receptor (AR) inhibitor
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Marco Oderda
Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
PSMA-PET/CT or PSMA-PET/MRI are more accurate imaging modalities compared to CT/BS; in approximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET up-stages the disease.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone, Prostate Cancer, Prostate Neoplasm
- Trial name
- OLIGOMET (NCT06430411)
- Testing
- Radical prostatectomy, Prostate irradiation, Surgical metastasectomy
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Node; Prostate, Bone Metastases
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
As in other solid tumours, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis compared with patients with extensive…
- Conditions
- Node; Prostate, Bone Metastases, Prostate Cancer Patients
- Trial name
- POSTCARD (NCT03795207)
- Testing
- SBRT + Durvalumab, SBRT
- Where
- 9 sites in France
- Volunteers
- 96 people
- Sponsor
- Institut Cancerologie de l'Ouest
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Prostate Cancer Recurrent
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
The current trial will test the combination of darolutamide with SBRT, in oligometastatic recurrent hormone sensitive prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- DART (NCT04641078)
- Testing
- Darolutamide, metastasis-directed treatment
- Where
- 8 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- University Hospital, Ghent
Prostate Cancer Metastatic to Bone
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone.
- Trial name
- RROPE (NCT03304418)
- Testing
- Radium Ra 223 Dichloride, Radiation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Oligometastatic Prostate Cancer
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission…
- Trial name
- POPSTAR II (NCT05560659)
- Testing
- 177Lu-PSMA
- Where
- 3 sites in Australia, Israel
- Volunteers
- 92 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia